Skip to main content
. Author manuscript; available in PMC: 2017 Mar 17.
Published in final edited form as: Circulation. 2011 Jul 5;124(3):335–345. doi: 10.1161/CIRCULATIONAHA.110.985150

Figure 1.

Figure 1

In study 1 (n=492), patients receiving regular statin treatment, had significantly better flow-mediated dilation (FMD) compared with those not receiving statins (A). In saphenous veins obtained from 256 of these patients during coronary artery bypass graft surgery, ex vivo vasorelaxations in response to acetylcholine (ACh) were significantly greater in subjects receiving statins (n=212) compared with those not receiving statins (n=44; B). In internal mammary artery samples obtained from these patients, vascular O2·− was significantly lower in those receiving statin treatment compared with those not receiving statins (C). The statin treatments in this population were simvastatin (63.1%), atorvastatin (26.8%), rosuvastatin (4.3%), pravastatin (3%), lovastatin (1.6%), and fluvastatin (1%). Values expressed as median (25th to 75th percentile; A and C) or mean±SEM (B). *P<0.01 vs no statin treatment (P values were derived from unpaired t test of the log-transformed values for A and C and by 2-way ANOVA for repeated measures for B).